Cargando…

Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection

Human Immunodeficiency Virus (HIV) is a retrovirus that can result in rare opportunistic infections occurring in humans. The onset of these infections is known as Acquired Immune Deficiency Syndrome (AIDS). Sexual transmission is responsible for the majority of infections 1, resulting in transmissio...

Descripción completa

Detalles Bibliográficos
Autores principales:	McConville, Christopher, Boyd, Peter, Major, Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988671/ https://www.ncbi.nlm.nih.gov/pubmed/24741339 http://dx.doi.org/10.4137/CMWH.S10353

Ejemplares similares

Vaginal drug delivery for the localised treatment of cervical cancer
por: Major, Ian, et al.
Publicado: (2017)

Vaginal deployment and tenofovir delivery by microbicide gels
por: Gao, Y., et al.
Publicado: (2015)

SPL7013 Gel (VivaGel®) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in Humans
por: Price, Clare F., et al.
Publicado: (2011)

Multicompartmental Pharmacokinetic Model of Tenofovir Delivery by a Vaginal Gel
por: Gao, Yajing, et al.
Publicado: (2013)

Mucosal effects of tenofovir 1% gel
por: Hladik, Florian, et al.
Publicado: (2015)

Inhibition of HIV and HSV infection by vaginal lactobacilli in vitro and in vivo
por: Zabihollahi, Rezvan, et al.
Publicado: (2012)

Tenofovir vaginal film as a potential MPT product against HIV-1 and HSV-2 acquisition: formulation development and preclinical assessment in non-human primates
por: Patel, Sravan Kumar, et al.
Publicado: (2023)

Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females
por: Tan, DHS
Publicado: (2012)

Correction: Mucosal effects for tenofovir 1% gel
por: Hladik, Florian, et al.
Publicado: (2015)

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
por: Thurman, Andrea Ries, et al.
Publicado: (2019)

A Multi-Compartment, Single and Multiple Dose Pharmacokinetic Study of the Vaginal Candidate Microbicide 1% Tenofovir Gel
por: Schwartz, Jill L., et al.
Publicado: (2011)

HSV-2- and HIV-1- permissive cell lines co-infected by HSV-2 and HIV-1 co-replicate HSV-2 and HIV-1 without production of HSV-2/HIV-1 pseudotype particles
por: LeGoff, Jérôme, et al.
Publicado: (2007)

Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention
por: Clark, Meredith R., et al.
Publicado: (2014)

VivaGel(™) (SPL7013 Gel): A candidate dendrimer – microbicide for the prevention of HIV and HSV infection
por: Rupp, Richard, et al.
Publicado: (2007)

A Macaque Model to Study Vaginal HSV-2/Immunodeficiency Virus Co-Infection and the Impact of HSV-2 on Microbicide Efficacy
por: Crostarosa, Federica, et al.
Publicado: (2009)

Mangiferin-Loaded Smart Gels for HSV-1 Treatment
por: Sicurella, Mariaconcetta, et al.
Publicado: (2021)

Ethosomal Gel for Topical Administration of Dimethyl Fumarate in the Treatment of HSV-1 Infections
por: Sicurella, Mariaconcetta, et al.
Publicado: (2023)

Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
por: Matthews, Lynn T., et al.
Publicado: (2013)

Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide
por: Ngandu, Nobubelo K., et al.
Publicado: (2017)

Vaginal rings for delivery of HIV microbicides
por: Malcolm, R Karl, et al.
Publicado: (2012)

Risk Factors for HSV-2 Infection among Sexual Partners of HSV-2/HIV-1 Co-Infected Persons
por: Mujugira, Andrew, et al.
Publicado: (2011)

MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments
por: Hendrix, Craig W., et al.
Publicado: (2013)

Natural Polyphenol-Containing Gels against HSV-1 Infection: A Comparative Study
por: Sicurella, Mariaconcetta, et al.
Publicado: (2022)

Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression
por: Romas, Laura, et al.
Publicado: (2016)

Enzyme Responsive Vaginal Microbicide Gels Containing Maraviroc and Tenofovir Microspheres Designed for Acid Phosphatase-Triggered Release for Pre-Exposure Prophylaxis of HIV-1: A Comparative Analysis of a Bigel and Thermosensitive Gel
por: Ekama, Sabdat Ozichu, et al.
Publicado: (2021)

Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring
por: Thurman, Andrea R., et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection
por: Duwal, Sulav, et al.
Publicado: (2012)

HIV-1 Replication in HIV-Infected Individuals Is Significantly Reduced When Peripheral Blood Mononuclear Cells Are Superinfected with HSV-1
por: Yamsuwan, Taneth, et al.
Publicado: (2012)

A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate
por: Yang, Kuo-Hsiung, et al.
Publicado: (2014)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
por: Wang, Huilian, et al.
Publicado: (2016)

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel
por: Archary, D, et al.
Publicado: (2016)

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women
por: McKinnon, Lyle R., et al.
Publicado: (2018)

Synthetic Mucin Gels with Self‐Healing Properties Augment Lubricity and Inhibit HIV‐1 and HSV‐2 Transmission
por: Kretschmer, Martin, et al.
Publicado: (2022)

Herbal Gel Formulation Developed for Anti-Human Immunodeficiency Virus (HIV)-1 Activity Also Inhibits In Vitro HSV-2 Infection
por: Mishra, Nripendra Nath, et al.
Publicado: (2018)

Chitosan-Based Mucoadhesive Vaginal Tablets for Controlled Release of the Anti-HIV Drug Tenofovir
por: Cazorla-Luna, Raúl, et al.
Publicado: (2019)

Correction: Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection
por: Duwal, Sulav, et al.
Publicado: (2012)

Negative epidemiological association between HSV-1 and HSV-2 infections
por: Nasrallah, Gheyath K., et al.
Publicado: (2019)

IgG in cervicovaginal mucus traps HSV and prevents vaginal Herpes infections
por: Wang, Ying-Ying, et al.
Publicado: (2014)

Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
por: Deeks, Emma D.
Publicado: (2018)

Release of Tenofovir from Carrageenan-Based Vaginal Suppositories
por: Zaveri, Toral, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s0fll3ig66q55n01k7edm1mdkq